tbuckley/cabot-search huggingface dataset:
Clinical accuracy of detecting recurrent prostate cancer lesions with F-18-Fluoroethylcholine or Ga-68-PSMA-HBED-CC PET/CT.
Authors: David J. K. P. Pfister, Daniel Porres, Axel Heidenreich, Florian Behrendt, Frederik Verburg
Journal: Journal of Clinical Oncology (2016)

218 Background: Ga-68-PSMA-HBED-CC (PSMA) is a novel and promising tracer for highly sensitive PET/CT diagnosis in recurrent prostate cancer (PCA). The aim of the present work was to assess the sensitivity, specificity, positive and negative predictive value (PPV/NPV) per lesion as well as the positive predictive value per patient of PSMA PET/CT in patients with recurrent prostate cancer referred for surgery after a positive PET/CT and to compare this with a collective of patients scanned using the current de-facto PET/CT standard tracer F-18-Fluoroethylcholine (FEC). Methods: In this retrospective study results of PET/CTs and post-surgical histological analysis were compared. 38 patients had FEC and 27 patients had PSMA. We performed a pelvic and/or retroperitoneal lymphadenectomy, if necessary supplemented by resection of locally recurrent lesions in accordance with imaging results. Results: In 30/38 FEC and 22/27 PSMA patients at least one focus of PCA was identified in postsurgical histology, leading to a PPV of 78.9% for FEC and 81.5% for PSMA. In FEC and PSMA patients a total of 378 and 308 lymph nodes and local lesions were removed, respectively. For FEC and PSMA the respective sensitivity was 71.2% and 86.9%, specificity 86.9% and 93.1%, PPV 67.3% and 75.7% and NPV 88.8% and 96.6%. Conclusions: In the present series PSMA PET/CT shows a somewhat better performance than the current de-facto PET/CT standard tracer FEC. Due to the very high NPV of PSMA PET/CT a selective locoregional lymphadenectomy involving only the regions affected on imaging can be discussed.
Stem Cell Numbers and Quality in a Group of Patients Undergoing Hip Replacement Surgery: Increasing Marrow Fat and Plasma IL-6 Concentrations with Aging.
Authors: Timothy R. McGuire, Susan K. Brusnahan, John Jackson, Ann M. Berger, Kevin L. Garvin, Judy Lane, Barbara J. Murphy, Anne Kessinger, John Graham Sharp
Journal: Blood (2006)
Monosomal Karyotype in Myeloid Malignancies Is Prognostically Worse Even After Allogeneic Hematopoietc Stem Cell Transplantaion; Results From Two Transplant Centers,
Authors: Minauchi Koichiro, Akio Shigematsu, Masanobu Nakata, Toshihiro Matsukawa, Koh Ebata, Tomohiro Yamakawa, Tomoyuki Saga, Kanako Shima, Makoto Ibata, Junichi Sugita, Shuichi Ota, Kiyotoshi Imai, Teiichi Hirano, Masahiro Ogasawara, Yoshio Kiyama, Masahiro Imamura, Naoki Kobayashi
Journal: Blood (2011)
Volume 103, July 3–December 5, 2008
Journal: Circulation Research (2008)

Aalkjaer C, 864

Abcouwer SF, e118

Abdullaev IF, 1289

Abe J-i, 269

Abrahani A, 252

Ackerman MJ, e81

Adamson SL, 24

Afonyushkin T, e1

Agrapart M, 432

Ahluwalia A, 957

Ahmed AI, 307

Ahmed Z, 957

Ahuja P, 1139

Aicher A, 796

Aiello A, 34

Aikawa M, 1402

Aitsebaomo J, 929

Akira S, 1402

Alitalo K, 1018, 1092, 1359

Allen BG, 733

Alves F, 536

Andersson LC, 1018

Angelini G, 1335

Angstenberger M, 61

Antzelevitch C, 396

Anversa P, 89, 107

Aoyama T, 98

Arai Y, 891

Aranha AB, 1319

Arcarese ML, 107

Arcelli D, 298

Archer SL, 1047

Ardehali A, 454

Arslan F, 334

Ascione R, 1335

Ashraf M, 1300

Athley E, 61

Atkins GB, 690

Atsma DE, 167

Attali B, 1451

Augustin H, 804

Averill MM, e116

Avkiran M, 307, 881

Baar K-M, 804

Babiker A, 1232

Bacchetti S, 34

Bache RJ, 1009

Backx PH, 527, 643, e120, 1345

Bader M, 1319

Baillie GS, 836

Baines A, 855

Baker AB, 289

Baltaev R, 1451

Baluk P, 1092

Ban K, 643

Baraban JM, 710

Barajas-Martinez HM, 396

Barateau V, 751

Barcelos LS, 1335

Baron EL, 1001

Bascands JL, 1335

Basson CT, e96

Bauge E, 450

Baye NL, 992

Bedel A, 694

Beech DJ, e97

Bekyarova T, 244

Belevych AE, 1466

Belmont PJ, 1249

Belperio JA, 454

Bendeck MP, 405

Bender JR, 328

Benjamin N, 957

Benndorf RA, 1037

Bennett M, 717

Bennett P, 855

Benson DW, 914

Benvenuti V, 34

Berbee M, 369

Bernabeu C, 1383

Berretta R, 1109

Bers DM, e105

Beuve A, 606

Beyer AM, 654

Bhanot S, 1173

Bhatti A, 643

Bicciato S, 298

Birney Y, 1370

Bisaillon JM, 1289

Biscetti F, 7

Bischoff J, 194

Bishopric NH, 125

Blackman BR, 671

Blanco FJ, 1383

Blatter LA, e105

Blobel CP, 916

Blombery P, 1084

Bobik A, …
Abstract 15621: Lack of Medical Insurance is an Independent Predictor of Increased Inter-Facility Transfer for St-Elevation Myocardial Infarction in U.S. Emergency Departments
Authors: Michael J Ward, Sunil Kripalani, Yuwei Zhu, Alan B Storrow, Thomas J Wang, Theodore Speroff, Daniel Munoz, Joseph L Fredi, Robert S Dittus, Frank E Harrell, Wesley H Self
Journal: Circulation (2014)

Introduction:  Only 31% of U.S. hospitals have primary percutaneous coronary intervention (PCI) capabilities for patients with ST-elevation myocardial infarction (STEMI). Lack of medical insurance has been shown to affect the decision to transfer from U.S. emergency departments (ED), but its effect on transfer to PCI centers for STEMI is unknown.   Hypothesis:  Lack of medical insurance is related to higher ED transfer rates for patients with STEMI.   Methods:  We used the Nationwide Emergency Department Sample (NEDS) to model predictors of transfer among ED patients diagnosed with STEMI between 2006 and 2011. Our multivariable logistic regression model included ED disposition as the outcome (transfer vs admit to same hospital), insurance status as the primary exposure (none, government, private, and other), controlling for age group, gender, year, US region, ED patient volume, household income in patient’s home zip code, and weekend presentation.   Results:  Our sample included 1,428,653 ED STEMI visits, including 259,376 (18.2%) transfers. STEMI transfer rates increased from 15% in 2006 to 20.5% in 2011. The adjusted odds ratio for transfer among self-pay patients compared with those with government insurance was 1.80 (95% CI 1.64,1.98) and compared to those with private insurance was 1.27 (95% CI 1.17,1.39) ( Table ).   Conclusions:  Controlling for other variables ( Table ), having no medical insurance was independently associated with higher transfer rates compared with having private or government insurance. These results suggest that insurance status influences the location of care for patients presenting to the ED with STEMI. Further research is required to explore illness severity and facility factors.
Graft-Versus-Host Disease Targets Ovary and Causes Infertility After Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Sonoko Shimoji, Koji Kato, Hidetsugu Tsujigiwa, Yoshihiro Eriguchi, Lifa Lee, Hidetaka Uryu, Shuichiro Takashima, Daigo Hashimoto, Koichi Akashi, Takanori Teshima
Journal: Blood (2013)
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis
Authors: Sonali Chaudhury, Nobuko HiJiya, Zhenhuan Hu, Rodney Sparapani, Matt E. Kalaycio, Edwin P. Alyea, Uday R. Popat, Wael Saber
Journal: Blood (2014)
The variations in symptom clusters related to well-being in palliative care patients during the final weeks of life
Authors: K. L. Olson, L. Hayduk, M. Cree, Y. Tsui, H. Quan, J. Hanson, P. Lawlor
Journal: Journal of Clinical Oncology (2007)

19612 Background: The purpose of this study was to determine whether the relationships between symptoms and well-being, as experienced by palliative care patients, changed as patients approached death. Methods: Data were extracted from a database that included Edmonton Symptom Assessment System scores collected from palliative care patients on Day 7 of Weeks 5 (n=123), 2 (n=115), and 1 (n=113) prior to death between 1995 and 2000. The model contained 18 effect parameters. Based on standard sample size requirements for structural equation modeling of 10 cases per indicator variable, the study was adequately powered for all three time points. The majority of patients had advanced cancer and were receiving care in either a tertiary palliative care or hospice setting. All participants had Folstein Mini- Mental Status Examination scores of 22 or higher at the time of original data collection. A causal model, based primarily on clinical discussions, linking pain, anxiety, nausea, shortness of breath, drowsiness, loss of appetite, tiredness, depression, and well-being was proposed. The model was tested against the data from all three time points, using LISREL, version 8.7.2s. Results: The model fit the data for all time points, but was revised slightly based on the modification indices. The final Goodness of Fit Test values were χ 2 = 4.2 (d.f.=8, p=.84), χ 2 = 13.3 (d.f.=9, p=.15), and χ 2 = 5.5 (d.f.=9, p=.79) respectively. With respect to tiredness, depression and well-being, the model explained at least 70% of the variance at Week 5, between 57% and 83% of the variance at Week 2, and 42% to 58% of the variance in Week 1. Nausea was unimportant in all of the models. The two strongest effects, persisting over all three time periods, were those linking anxiety to depression, and drowsiness to tiredness, reflecting strong stability in patient rankings even as health declined and treatment changed. Conclusions: The symptom clusters in this study changed over time, in disagreement with existing research that assumes the relationships between symptoms within symptom clusters remain stable. An improved understanding of alterations in symptom clusters may contribute to improved control of patient comfort, quality of life, and quality of death. No significant financial relationships to disclose.
GW26-e4626 Percutaneous transluminal coil embolization of septal artery for ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy
Authors: Qingan Jiang, Hui liu, Lan Zhang, Hongwen Tan, Yongyao Yang, Tianhe Yang
Journal: Journal of the American College of Cardiology (2015)
Obstetric Facility Quality and Newborn Mortality in Malawi: A Cross-Sectional Study
Authors: Hannah H. Leslie, Günther Fink, Humphreys Nsona, Margaret E. Kruk
Journal: PLoS Medicine (2016)

Background Ending preventable newborn deaths is a global health priority, but efforts to improve coverage of maternal and newborn care have not yielded expected gains in infant survival in many settings. One possible explanation is poor quality of clinical care. We assess facility quality and estimate the association of facility quality with neonatal mortality in Malawi. Methods and Findings Data on facility infrastructure as well as processes of routine and basic emergency obstetric care for all facilities in the country were obtained from 2013 Malawi Service Provision Assessment. Birth location and mortality for children born in the preceding two years were obtained from the 2013–2014 Millennium Development Goals Endline Survey. Facilities were classified as higher quality if they ranked in the top 25% of delivery facilities based on an index of 25 predefined quality indicators. To address risk selection (sicker mothers choosing or being referred to higher-quality facilities), we employed instrumental variable (IV) analysis to estimate the association of facility quality of care with neonatal mortality. We used the difference between distance to the nearest facility and distance to a higher-quality delivery facility as the instrument. Four hundred sixty-seven of the 540 delivery facilities in Malawi, including 134 rated as higher quality, were linked to births in the population survey. The difference between higher- and lower-quality facilities was most pronounced in indicators of basic emergency obstetric care procedures. Higher-quality facilities were located a median distance of 3.3 km further from women than the nearest delivery facility and were more likely to be in urban areas. Among the 6,686 neonates analyzed, the overall neonatal mortality rate was 17 per 1,000 live births. Delivery in a higher-quality facility (top 25%) was associated with a 2.3 percentage point lower newborn mortality (95% confidence interval [CI] -0.046, 0.000, p-value 0.047). These results imply a newborn mortality rate of 28 per 1,000 births at low-quality facilities and of 5 per 1,000 births at the top 25% of facilities, accounting for maternal and newborn characteristics. This estimate applies to newborns whose mothers would switch from a lower-quality to a higher-quality facility if one were more accessible. Although we did not find an indication of unmeasured associations between the instrument and outcome, this remains a potential limitation of IV analysis. Conclusions Poor quality of delivery facilities is associated with higher risk of newborn mortality in Malawi. A shift in focus from increasing utilization of delivery facilities to improving their quality is needed if global targets for further reductions in newborn mortality are to be achieved.
Selective Migration of CD18+ Neutrophils into the Tissue Results in Reversal of the Phenotype in Canine Leukocyte Adhesion Deficiency.
Authors: Yuchen Gu, Robert A. Sokolic, Thomas R. Bauer, Laura M. Tuschong, Mehreen Hai, Tanya Burkholder, John Bacher, Matthew F. Starost, Dennis D. Hickstein
Journal: Blood (2005)
GP is struck off for a string of hurried and wrong diagnoses
Authors: Clare Dyer
Journal: BMJ (2016)

A 72 year old locum GP who made a string of hurried and wrong diagnoses has been struck off the medical register after he refused to undertake a clinical audit of his work or provide any evidence that he had kept his skills up to date.

Jagjit Singh Pawar, who trained in India, worked as a single handed GP in Gravesend, Kent for nearly 20 years until 1999 before resigning and taking on various locum posts across the south of England.

But a pattern of complaints from patients and employers between 2011 and 2013 led the General Medical Council (GMC) to investigate a number of his consultations carried …
Thyroid-Stimulating Hormone in the Evaluation of Subclinical Hypothyroidism
Authors: Maria Papaleontiou, Anne R. Cappola
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
GW26-e1362 Activation of Cannabinoid Receptor 2 improves therapeutic efficacy of Adipose-Derived Mesenchymal Stem Cells to alleviate myocardial ischemia injury through AMPK/SIRT1 and TLR4/NF-κB Signaling Pathways
Authors: Dong Han, Sai Ma, Xiang Li, Zhenhua Jiang, Xiujuan Li, Miaomiao Fan, Feng Cao
Journal: Journal of the American College of Cardiology (2015)
Skewing of the T-Cell Receptor Repertoire in Patients Receiving Rituximab after Allogeneic Hematopoietic Cell Transplantation: What Lies Beneath?
Authors: Apostolia Papalexandri, Maria Karypidou, Evangelia Stalika, Michail Iskas, Anna Vardi, Tasoula Touloumenidou, Panagiota Zerva, Evangelia Yannaki, Despina Mallouri, Ioannis Batsis, Anastasia Hadzidimitriou, Achilles Anagnostopoulos, Ioanna Sakellari, Kostas Stamatopoulos
Journal: Blood (2014)
Outcomes for Patients Aged 60 and Over Are Similar to Younger Patients Following Reduced-Intensity Allogeneic Stem Cell Transplant for CLL
Authors: Cynthia L. Toze, Chinmay B. Dalal, Thomas J. Nevill, Michael J. Barnett, Stephen H. Nantel, Donna L. Forrest, Donna E. Hogge, Heather J. Sutherland, Kevin W. Song, Yasser Abou Mourad, Raewyn Broady, Maryse M. Power, Sujaatha Narayanan, Tanya L. Gillan, Clayton A. Smith, John D. Shepherd
Journal: Blood (2011)
Increased HER2 expression in women with recurrent ER positive breast cancer
Authors: V. G. Kaklamani, J. Cicconi, W. Gradishar, E. Willey, L. Diaz, A. Rademaker, R. O'Regan
Journal: Journal of Clinical Oncology (2007)

10516 Introduction: Tamoxifen (TAM) remains widely used in the treatment of all stages of breast cancer. Although the majority of hormone receptor (HR) positive tumors respond to TAM, many of these breast cancers will develop resistance resulting in disease recurrence or progression. Over-expression of HER2 appears to play a role in de novo tamoxifen-resistance. We have demonstrated previously that HR-positive breast cancers exposed to selective estrogen receptor modulators (SERMs), such as tamoxifen, in vivo continue to express HR but have an increase in the expression of HER2 (O'Regan Clin Cancer Res 2006). However the above finding has not been confirmed in patient samples. Materials and Methods: We evaluated 30 paired tissue samples from patients with HR positive tumors whose cancers recurred. The first tissue sample is from diagnosis and the paired sample comes from metachronous metastatic disease. Results: The median age of diagnosis was 56 (29–96). Seven patients presented with stage I disease, 11 with stage II and nine with stage III3, and three patients had missing staging information. The median time to recurrence was three years. The expression of ER decreased from diagnosis to recurrence from 79% to 59% (p=0.035). PR also decreased between diagnosis and recurrence from 34% to 22% (p=0.13). HER2 score was 2 or 3 in 27% of samples at diagnosis and in 53% at time of recurrence (p=0.01). These cancers did not have HER2 gene amplification. Conclusions: These results confirm our in vivo findings that over-expression of HER2 plays a significant role in acquired TAM- resistance. We have previously demonstrated that trastuzumab inhibits growth of SERM-resistant breast cancers in vivo despite the fact that these cancers did not have HER2 gene amplification. Taken together, our findings suggest that trastuzumab should be examined clinically in patients with TAM-resistant metastatic breast cancer, as they may be particularly sensitive to inhibition of HER2-driven pathways. No significant financial relationships to disclose.
Phase II study of gemcitabine and cisplatin in previously untreated metastatic or recurrent advanced esophageal cancer: A Chinese esophageal cancer group
Authors: J. Huang, X. Q. Fan, L. Chen, N. A. Liu, G. R. Cai, R. X. Zhang, W. J. Wang, Y. Sun
Journal: Journal of Clinical Oncology (2006)

14015 Background: Esophageal cancer is one of the most frequent malignancies and the second leading cause of death from cancer in some area in China. The combination of gemcitabine and cisplatin acts synergistically in the treatment of some solid tumors, such as lung cancer, head and neck cancer etc. We performed a phase II trial of gemcitabine in combination with cisplatin for esophageal cancer. The antitumor response, toxicity and survival of patients treated with the two-drug regimen were evaluated. Methods: Patients with chemotherapy-naive metastatic or recurrent advanced squamous cell carcinoma of the esophagus were treated with Gemcitabine at 1000mg/m 2 over 30–60 minutes on days 1, 8 and cisplatin 40mg/m 2 on days 1, 2. Cycles were repeated every 21 days. Granulocyte colony-stimulating factor (G-CSF) was not routinely administered unless the patient had neutropenia. Results: Thirty-four eligible patients were accrued and 26 patients were evaluable for response. Major objective responses were observed in 15 patients (57.7%), including two complete responses (7.7%) and thirteen partial responses(50.0%). All patients with response were confirmed again after four weeks. 28 patients were evaluable for toxicity. Non-haematological toxicity consisted 7.1% (2 patients) grade 3/4 nausea/vomiting. Myelosupression was the most common toxicity. 39.3% patients occurred grade 3/4 myelosuppression. Conclusion: This cisplatin-gemcitabine regimen was manageable and had significant activity in patients with advanced esophageal cancer. No significant financial relationships to disclose.
GW26-e2336 Association between the NFKB1-94ATTG ins/del polymorphism (rs28362491) and coronary artery disease: A meta-analysis
Authors: Qingjie Chen, Yun Zhou, Hongmei Lai, Yining Yang, Xiaomei Li, Hui Zhai, Junyi Luo, Fen Liu, Bangdang Chen, Xiaocui Chen, Yitong Ma
Journal: Journal of the American College of Cardiology (2015)
Early phase I study of the PARP inhibitor veliparib (ABT-888) alone or in combination with carboplatin/paclitaxel (CP) in patients with varying degrees of hepatic or renal dysfunction: A study of the NCI-Organ Dysfunction Working Group (ODG).
Authors: Hussein Abdul-Hassan Tawbi, Edward Chu, Yan Lin, David Michael Hyman, Sanjay Goel, Michelle A. Rudek, Afshin Dowlati, Patricia LoRusso, Daniel Mulkerin, Helen K. Chew, Brian Kiesel, Laura Pollice, Leonard Joseph Appleman, Shannon Puhalla, Ronald G. Stoller, James J. Lee, Percy Ivy, Jan H. Beumer
Journal: Journal of Clinical Oncology (2014)

2572 Background: PARP inhibitors are promising anti-cancer agents with clinical activity as single agents or in combination with chemotherapy. Alteration of hepatic or renal function could affect the pharmacokinetic (PK) characteristics of veliparib (V) and thus, impact adversely on its safety. We conducted a multi-center Phase I study through the NCI-Organ Dysfunction Working Group (ODG) to determine: (1) the maximum tolerated dose (MTD) of V in combination with CP in pts with varying degrees of renal or hepatic dysfunction; and (2) the PK of V. Methods: Pts with advanced solid malignancies, ECOG PS 0-2, and normal bone marrow were enrolled to the following cohorts: normal (N); moderate (R2; CrCL= 30-59mL/min), severe (R3; CrCL<30mL/min) renal dysfunction, and hemodialysis (R4); mild (H2; bilirubin(B)<1.25x ULN), mild with transaminase elevation (H3; B<1.25x ULN and ALT/AST(T)>3xULN), moderate (H4; B>1.25-2xULN and T<10xULN), and severe (H5; B>2-5xULN and T<10xULN) hepatic dysfunction. Pts with both renal and hepatic dysfunction were excluded. All pts received a single 80 mg oral dose of V for extensive PK sampling 1 week prior to the initiation of combination therapy. V dose escalation up to 80 mg PO BIDx5d followed the standard "3+3" design within each cohort with C AUC 6 and P 175 mg/m2 on d3 of a 21-d cycle. C and P were dose-adjusted to the degree of organ dysfunction following FDA dosing guidelines. DLTs were defined based on myelosuppression or worsening organ function. Results: A total of 59 pts were enrolled of which 45 were evaluable: N: 13, R2: 11, R3: 6, H2: 7, H3: 3, H4: 4. All pts enrolled on DL1 and DLminus1 of H4 experienced DLTs closing accrual to this cohort and H5. PK data on V and its inactive metabolite M8 were available on all pts treated with a single fixed dose V. Conclusions: V combined with CP is not safely deliverable in pts with moderate to severe hepatic dysfunction, though V PK appeared unaffected by hepatic dysfunction. Renal dysfunction did result in increased V and M8 exposure. These data will guide potential dose reductions in pts with hepatic or renal dysfunction. Clinical trial information: NCT01366144.